IN10028, a next-generation FAK inhibitor discovered for the treatment of solid tumors
DOI:
文献链接: https://doi.org/10.1158/1538-7445.AM2026-5867
其他信息:
B Zhang, H Wang, J Gao, F Xi, L Liu, L Liu…
Cancer …, 2026
aacrjournals.org
The development of small-molecule inhibitors targeting Focal Adhesion Kinase (FAK) has been ongoing for several decades. In May 2025, the FDA approved a combination therapy involving FAK and MEK/RAF inhibitors for the treatment of low-grade serous ovarian cancer, marking a significant advancement in FAK-targeted therapies. In this study, we present IN10028, a second-generation FAK inhibitor that demonstrates enhanced efficacy in combination therapies and favorable safety profiles. IN10028 effectively targets both FAK1 …

